The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
FAK inhibitors in Cancer, a patent review
Abstract
INTRODUCTION: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of the ECM. FAK is known to regulate cell survival, proliferation and migration. AREAS COVERED: FAK expression has also been shown to be up-regulated in many cancer types. Previous study also indicates that FAK-mediated signaling and functions are intrinsically involved in the progression of tumor aggressiveness, suggesting that FAK is a promising target for anticancer therapies. Small molecule FAK inhibitors have been developed and are being tested in clinical phase trials. EXPERT OPINION: These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addition to reducing metastasis and angiogenesis. In this review, we give updates on the design, synthesis and structure-activity relationship analysis of small molecule FAK inhibitors discovered from 2015 until now. We also review the FAK inhibitors that are in clinical development and highlight the future prospects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cell mechanics and the cytoskeleton
Fletcher, D. A., & Mullins, R. D. (2010) · Nature · doi:10.1038/nature08908 · Cited by 3,195
Focal adhesion kinase: in command and control of cell motility
Mitra, S. K., Hanson, D. A., & Schlaepfer, D. D. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1549 · Cited by 2,657
Focal adhesion kinase: the first ten years
Parsons, J. T. (2003) · Journal of Cell Science · doi:10.1242/jcs.00373 · Cited by 1,389
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,323
Signaling through focal adhesion kinase
Schlaepfer, D. D., Hauck, C. R., & Sieg, D. J. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00052-2 · Cited by 1,181
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
Schaller, M. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.045112 · Cited by 613
Signal transduction by focal adhesion kinase in cancer
Zhao, J., & Guan, J. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9165-4 · Cited by 608
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407
The FERM domain: organizing the structure and function of FAK
Frame, M. C., Patel, H., Serrels, B., Lietha, D., & Eck, M. J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2996 · Cited by 387
Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271
Roberts, W. G., Ung, E. J., Whalen, P. M., Cooper, B. A., Hulford, C. A., Autry, C., Richter, D., Emerson, E., Lin, J., Kath, J. C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5155 · Cited by 381
Expression of focal adhesion kinase gene and invasive cancer
Weiner, T. M., Craven, R. J., Cance, W. G., & Liu, E. T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92881-s · Cited by 339
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells
Agochiya, M., Brunton, V. G., Owens, D. W., Parkinson, E. K., Paraskeva, C., Keith, W. N., & Frame, M. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202957 · Cited by 242
Tremblay, L., Hauck, W., Aprikian, A. G., Bégin, L. R., Chapdelaine, A., & Chevalier, S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961009)68:2 · Cited by 232
Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma
Judson, P. L., He, X., Cance, W. G., & Le, L. V. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:6 · Cited by 181
Lark, A. L., Livasy, C., Calvo, B. F., Caskey, L. S., Moore, D., Yang, X., & Cance, W. G. (2003) · PubMed · Cited by 170
Focal adhesion kinase and tumour angiogenesis
Lechertier, T., & Hodivala‐Dilke, K. (2011) · The Journal of Pathology · doi:10.1002/path.3018 · Cited by 169
Buckbinder, L., Crawford, D. T., Qi, H., Ke, H. Z., OLSON, L. M., Long, K. R., Bonnette, P. C., Baumann, A. P., Hambor, J., GRASSER, W. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701421104 · Cited by 163
van Nimwegen, M. J., Verkoeijen, S., van Buren, L., Burg, D., & van de Water, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4126 · Cited by 131
Canel, M., Secades, P., Rodrigo, J. P., Cabanillas, R., Herrero, A., Suarez, C. M., & Chiara, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1583 · Cited by 116
Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression
Lim, S., Miller, N. L. G., Chen, X. L., Tancioni, I., Walsh, C. T., Lawson, C., Uryu, S. A., Weis, S. M., Cheresh, D. A., & Schlaepfer, D. D. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201109067 · Cited by 114
Han, S., Mistry, A., Chang, J. S., Cunningham, D., Griffor, M., Bonnette, P. C., Wang, H., Chrunyk, B. A., Aspnes, G. E., Walker, D. P., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809038200 · Cited by 110
Focal Adhesion Kinase as a Cancer Therapy Target
Golubovskaya, V. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728648 · Cited by 105
The role of FAK in tumor metabolism and therapy
Zhang, J., & Hochwald, S. N. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.003 · Cited by 104
Targeting focal adhesion kinase signaling in tumor growth and metastasis
Schwock, J., Dhani, N. C., & Hedley, D. W. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903460340 · Cited by 103
Ott, G. R., Cheng, M. M., Learn, K. S., Wagner, J., Gingrich, D. E., Lisko, J. G., Curry, M. A., Mesaros, E. F., Ghose, A. K., Quail, M. R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00487 · Cited by 97
Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer
Schultze, A., & Fiedler, W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.489548 · Cited by 94
Walker, D. P., Zawistoski, M. P., McGlynn, M. A., Li, J., Kung, D. W., Bonnette, P. C., Baumann, A. P., Buckbinder, L., Houser, J. A., Boer, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.093 · Cited by 88
Focal adhesion kinase inhibitors are potent anti‐angiogenic agents
Cabrita, M. A., Jones, L., Quizi, J. L., Sabourin, L. A., McKay, B. C., & Addison, C. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.10.004 · Cited by 86
Dao, P., Smith, N., Tomkiewicz, C., Yen‐Pon, E., Camacho‐Artacho, M., Lietha, D., Herbeuval, J.-P., Coumoul, X., Garbay, C., & Chen, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500784e · Cited by 62
Structure-based discovery of cellular-active allosteric inhibitors of FAK
Tomita, N., Hayashi, Y., Suzuki, S., Oomori, Y., Aramaki, Y., Matsushita, Y., Iwatani, M., Iwata, H., Okabe, A., Awazu, Y., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.047 · Cited by 59
Walker, D. P., Bi, F. C., Kalgutkar, A. S. S., Bauman, J. N., Zhao, S. X., Soglia, J. R., Aspnes, G. E., Kung, D. W., Klug-McLeod, J. L., Zawistoski, M. P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.030 · Cited by 57
Discovery and characterization of novel allosteric FAK inhibitors
Iwatani, M., Iwata, H., Okabe, A., Skene, R. J., Tomita, N., Hayashi, Y., Aramaki, Y., Hosfield, D. J., Hori, A., Baba, A., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.06.035 · Cited by 54
Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth
Canel, M., Byron, A., Sims, A. H., Cartier, J., Patel, H., Frame, M. C., Brunton, V. G., Serrels, B., & Serrels, A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0418 · Cited by 54
Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity
Dao, P., Lietha, D., Ethève‐Quelquejeu, M., Garbay, C., & Chen, H. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.02.072 · Cited by 52
Scaffold mining of kinase hinge binders in crystal structure database
Xing, L., Rai, B., & Lunney, E. A. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9700-4 · Cited by 42
Qu, M., Liu, Z., Zhao, D. Y., Wang, C., Zhang, J., Tang, Z., Liu, K., Shu, X. H., Yuan, H., & Ma, X. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.044 · Cited by 39
Schoenherr, C., Byron, A., Sandilands, E., Paliashvili, K., Baillie, G. S., García-Muñoz, A., Valacca, C., Cecconi, F., Serrels, B., & Frame, M. C. (2017) · eLife · doi:10.7554/elife.23172 · Cited by 38
Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy
Ma, W. W. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011796817628 · Cited by 37
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency
Farand, J., Mai, N., Chandrasekhar, J., Newby, Z. E. R., Veldhuizen, J. J. V., Loyer-Drew, J., Venkataramani, C., Guerrero, J., Kwok, A., Li, N., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.092 · Cited by 37
Schultze, A., Decker, S., Otten, J., Horst, A. K., Vohwinkel, G., Schuch, G., Bokemeyer, C., Loges, S., & Fiedler, W. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9326-5 · Cited by 35
FAK goes nuclear to control antitumor immunity—a new target in cancer immuno-therapy
Serrels, A., & Frame, M. C. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119356 · Cited by 18
Research works printed but not linked: 2
- Xu Q, 2015, From PCT Int Appl, WO 2015120289 A
- Pachter JA, 2017, PCT Int Appl, WO 2017004192 A
Cited by
Sorted by citations
The Extracellular Matrix Modulates the Metastatic Journey
Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 561
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Self-citationKciuk, M., Alam, M., Ali, N., Rashid, S., Głowacka, P., Rajamanikandan, S., Çeli̇k, İ., Yahya, E. B., Dubey, A., Zerroug, E., et al. (2023) · Molecules · doi:10.3390/molecules28135246 · Cited by 148
Setargew, Y. F. I., Wyllie, K., Grant, R. D., Chitty, J. L., & Cox, T. R. (2021) · Cancers · doi:10.3390/cancers13030491 · Cited by 114
Jia, Y., Hu, J., An, K., Zhao, Q., Dang, Y., Liu, H., Zhao, W., Geng, S., & Xu, F. (2023) · Nature Communications · doi:10.1038/s41467-023-38209-x · Cited by 115
Metadata
- Authors
- Lv, P.-C., Jiang, A.-Q., Zhang, W.-M., & Zhu, H.-L.
- Affiliations
- State Key Laboratory of Pharmaceutical Biotechnology (CN)
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing P. R. China
- Corresponding author
- Jiang, Ai-Qin
- Zhu, Hai-Liang
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2017-12-13
- Volume
- 28
- Issue
- 2
- Pages
- 139-145
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2775554376
- Cited by
- 114
- References
- 42
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 19 · 2023: 12 · 2022: 16 · 2021: 23 · 2020: 15 · 2019: 15 · 2018: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Patents (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- focal adhesion kinase, FAK inhibitors, small molecule inhibitors, non-receptor tyrosine kinase, integrin signaling, extracellular matrix, anticancer drug design, structure-activity relationship, tumor progression, metastasis, angiogenesis, apoptosis, clinical development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Patents as Topic, Structure-Activity Relationship, Drug Design, Gene Expression Regulation, Neoplastic, Disease Progression, Protein Kinase Inhibitors, Focal Adhesion Protein-Tyrosine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
